Eli Lilly and Company (NYSE:LLY) is one of Goldman Sachs’s top growth stock picks. On February 18, Eli Lilly and Company (NYSE:LLY) said using Taltz (ixekizumab) together with Zepbound (tirzepatide) worked better than Taltz alone in adults who had moderate-to-severe plaque psoriasis and also had obesity or were overweight. Eli Lilly (LLY) Expands Pipeline With Positive Trial Data and New Licensing Deal Eli Lilly said the results came from its Phase 3b TOGETHER-PsO study, which tested Taltz alone vs. Talt ...

Group 1: Company Performance and Developments - Eli Lilly and Company (NYSE: LLY) is recognized as a strong long-term growth stock, with Jefferies reaffirming a Buy rating and setting a price target of $1,300.00 following positive trial results for its drugs Taltz and Zepbound [1] - The TOGETHER-PsA study demonstrated that the combination of Taltz and Zepbound achieved a primary endpoint of 50% improvement in psoriatic arthritis activity and a weight drop of ≥10%, outperforming Taltz monotherapy [2] - Eli Lilly announced the acquisition of Ventyx Biosciences, a clinical-stage biopharmaceutical company, for $14.00 per share, totaling an equity value of approximately $1.2 billion [3][4] Group 2: Drug Efficacy and Market Position - The combination of Taltz and Zepbound resulted in a 64% relative increase in patients achieving ACR50 compared to Taltz alone, marking Taltz as the first biologic with comprehensive treatment data for psoriatic arthritis [2] - Eli Lilly is actively securing its position in the obesity drug market, leveraging the efficacy of its products to enhance its competitive edge [2]

Core Insights - Oruka Therapeutics is developing ORKA-002, a novel monoclonal antibody with an extended half-life targeting IL-17A/F, which shows potential for less frequent dosing compared to existing therapies [1][3][6] - The half-life of ORKA-002 in non-human primates (NHP) exceeds 30 days, which is over three times longer than bimekizumab, suggesting a dosing interval of two to three times per year [1][6] - ORKA-002 demonstrates equivalent potency to bimekizumab with similar binding affinity, indicating a promising profile for treating chronic skin diseases like plaque psoriasis and psoriatic arthritis [2][3][6] Company Overview - Oruka Therapeutics aims to set a new standard for treating chronic skin diseases, focusing on achieving high rates of complete disease clearance with infrequent dosing [4] - The company is advancing a proprietary portfolio of antibodies engineered to target the core mechanisms of plaque psoriasis and other dermatologic conditions [4] Product Details - ORKA-002 is administered subcutaneously and has shown superior efficacy in preclinical studies compared to existing therapies that require monthly maintenance dosing [3][6] - Projections indicate that ORKA-002 could have a human half-life of approximately 50 to 75 days, allowing for dosing intervals of once every four months or twice a year [6]